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Abstract
Purpose—Pharmacogenetic (PGx) testing is one of the primary drivers of personalized
medicine. The use of PGx testing may provide a lifetime of benefits through tailoring drug dosing
and selection of multiple medications to improve therapeutic outcomes and reduce adverse
responses. We aimed to assess public interest and concerns regarding sharing and storage of PGx
test results that would facilitate the re-use of PGx data across a lifetime of care.
Methods—We conducted a random-digit-dial phone survey of a sample of the U.S. public.
Results—We achieved an overall response rate of 42% (n=1,139). Most respondents indicated
they were extremely or somewhat comfortable allowing their PGx test results to be shared with
other doctors involved in their care management (90% ± 2.18%); significantly fewer respondents
(74% ± 3.27%) indicated they were extremely or somewhat comfortable sharing results with their
pharmacist (p<0.0001).
Conclusion—Patients, pharmacists, and physicians will all be critical players in the
pharmacotherapy process. Patients are supportive of sharing PGx test results with physicians and
pharmacists as well as personally maintaining their test results. However, further study is needed
to understand which options are needed for sharing, appropriate storage and patient education
about the relevance of PGx test results to promote consideration of this information by other
prescribing practitioners.
INTRODUCTION
Pharmacogenetic (PGx) testing, or the use of genetic tests to determine the optimal
pharmaceutical therapy for a given individual, is considered to be one of the most promising
early clinical applications arising from genomics research, with the potential to reduce the
prevalence of adverse drug responses and improve efficacy.1,2 A number of drugs are
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metabolized by a handful of highly polymorphic cytochrome P-450 liver enzymes.3 Over a
person’s lifetime, they are likely to be prescribed several medications for which these and
other genes have an important role in determining the rate of metabolism. Thus, the results
of a PGx test will be pertinent not only to the immediate clinical situation for which testing
is initially ordered but likely for future clinical encounters. As we enter the PGx era, it is
imperative to consider how relevant PGx results should be managed with respect to storage
and access to minimize information fragmentation and duplicate testing.4 As PGx testing
assay costs and their cost-effectiveness for a single clinical decision is a major barrier to the
routine clinical application of PGx, the ability to re-use PGx data across a lifetime of care
could significantly facilitate the use of such testing in routine practice.
As part of a national survey exploring public interest and attitudes toward PGx testing and
specifically, ancillary information revealed by PGx testing, we asked respondents about
sharing and storage of PGx test results. To our knowledge, no studies have examined this
important issue essential to ensuring the lifetime benefits of PGx testing. In this paper, we
discuss the benefits and limitations of several options of storage and access of PGx results
informed by findings from a national public survey on PGx testing on sharing results with
other physicians and pharmacists and patient management of results.
MATERIALS AND METHODS
Survey Development & Administration
As described elsewhere,5 we developed a survey to explore public attitudes regarding PGx
testing and the potential for ancillary information. Specifically, the final survey was
comprised of several sections including personal and family experience with medications,
interest in PGx testing given certain risks and uses of testing, sharing and management of
test results and attitudes towards management of ancillary information revealed by PGx
testing. We report here data regarding public attitudes towards sharing and management of
test results [see Haga et al, 2011 and Haga et al., 2011 for other survey findings].5,6
The survey was first piloted on a random sample of the local North Carolina population
before launching the national survey in fall 2009. A random digit dial sample of telephone
numbers in the continental U.S. was selected for the national survey and stratified by U.S.
census regions to ensure representativeness. Eligibility was based on reaching a household
with an English-speaking resident, 18 years of age or older. If more than one eligible adult
resided in the household, one was randomly selected.
Data Analysis
Descriptive statistical analysis was conducted to examine respondent demographics and
attitudes toward sharing and management of PGx test results. For logistic regression
analyses, model building was based on hypothetically-related covariates with adjustment for
demographic characteristics; final variable selection was conducted using the backward
selection approach. Odds ratios and corresponding 95% confidence intervals were
computed; a significance level of 0.05 was used for all statistical tests. To adjust for control
variables, Cochran-Mantel-Haenszel (CMH) test was applied when comparing two groups
on a binary response. All analyses were conducted in SAS (Version 9.1.3 using Proc
Frequency, Proc Logistic & Proc Regression).
RESULTS
A response rate was 42%7 was achieved in this survey. Because respondents tended to be
older (51% were 55 or older), White (86%), and female (61%) to a greater extent than would
be expected by chance alone, the survey data were adjusted by age (18–34, 35–54, 55 &
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older), race (White & non-White), and gender based on normative data from the 2008
American Community Survey.8 After post-stratification, the adjusted sample better reflected
the U.S. population (51% female, 78% White, and 31% 55 or older). To further reduce the
potential effect of bias, non-response adjustments were predicated on U.S. census regions.
After assessing respondents’ likelihood to undergo PGx testing given a range of uses and
risks, we asked respondents to indicate their level of comfort regarding sharing and
management of their PGx results. In response to a question about their level of comfort in
allowing test results to be shared with their other doctors, most respondents indicated that
they were extremely or somewhat comfortable allowing their PGx test results to be shared
with other doctors involved in their care management (90% ± 2.18%). In addition, it was
found that respondents who had excellent/good health were less likely to be comfortable
sharing results with other doctors (OR=0.45, p=0.007, CI [0.25–0.80]).
When asked about their level of comfort regarding sharing of their PGx test result with a
pharmacist, 74% (± 3.27%) of respondents indicated that they were extremely or somewhat
comfortable sharing the results with their pharmacist. There were no respondent variables
found to be significantly associated with level of comfort regarding sharing results with a
pharmacist. However, after adjusting for sex, age group, level of education, and race, there
was a statistically significant difference in the proportion of respondents who indicated that
they were comfortable sharing their results with other doctors and the proportion of
respondents who were comfortable sharing their results with their pharmacist (CMH statistic
= 144.70, p < 0.0001).
When asked about how comfortable they would be keeping their PGx results in a personal
record, such as stored on a card kept in the patient’s wallet or purse, 70% (± 3.54%) of
respondents felt extremely or somewhat comfortable with this option for data storage. No
respondent variables were associated with level of comfort in keeping their PGx results.
DISCUSSION
The problems associated with medical information fragmentation have been demonstrated in
both primary care and specialty settings,9–11 potentially resulting in adverse outcomes or
delay of treatment.10 In addition, missing medical information could lead to duplicate
testing,4 potentially resulting in delayed treatment and wasted resources. As indicated by our
survey findings, the public appears comfortable having their PGx results shared with their
treating physician(s), which would help avoid duplicate testing. To promote sharing of
results during this early stage of use of PGx testing, it will be necessary to emphasize to
patients the importance of these results for any future medical treatments prescribed and the
need to inform new treating physicians about their results. In addition, physicians should
begin to ask patients about previous PGx testing that may inform treatment. Similar to
routinely asked questions regarding drug allergies, we could envision patients routinely
queried about PGx testing for P450 enzymes and classification as a poor metabolizer (PM),
intermediate metabolizer (IM), or ultra-rapid metabolizer (UM). However, given that self-
reported drug allergies are often inaccurate, leading to unnecessary avoidance of drugs,12–14
expecting patients to accurately recall and report their CYP metabolic status, much less their
genotype, may be overly ambitious until the public becomes more knowledgeable about
testing and the type of information provided by the test. Therefore, options are needed for
appropriate storage and patient education about the relevance of PGx test results to promote
consideration of this information by other prescribing practitioners. We speculate that
healthy respondents may be less likely to be comfortable sharing results with other
physicians due to concerns about privacy: their perceived benefit from sharing this private
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information may be less than the perceived costs, e.g., with regard to potential life insurance
discrimination.
Haga & Burke15 proposed that PGx results be retained by either patients or stored in
pharmacy databases to maximize consideration of PGx test results for new treatments.
Errors in self-reporting and recall may be avoided if PGx test results were stored in a
personal health record. The use of personal health records has been gradually expanding16 as
is physician willingness to use such records,17 which may improve the quality of care.18
Given that respondents indicated they would be comfortable maintaining their PGx results,
testing laboratories could enable results to be accessible to patients in addition to sending the
results to the physician’s office. For example, the genetic testing company Navigenics,
which up until recently provided testing directly to consumers, presented PGx test results
(test interpretation not genotype) in a card format to be shared with physicians, listing the
target drug, their risk of side effect, and the implications of their result. Patients would then
be responsible for providing the PGx results to new providers when drugs are prescribed.
Particularly in acute care situations, if this information is stored electronically on an easily
accessible physical device (e.g., an insurance card) or on a secure Web site, the information
could be quickly retrieved and considered when testing is not otherwise feasible. However,
about one-third of participants of a PGx testing study indicated that they would not share
their results with their physicians due to perceived physician disinterest, incompetence, or
burden.19 Other potential barriers to patient sharing may include concerns about privacy,
stigmatization, discrimination, coverage and/or access to potential treatments.
Another option may be to provide access of PGx test results to pharmacists. Pharmacists
already play an important role in assuring the safety of drug therapy by assessing potential
adverse drug interactions when a new drug is prescribed, and by providing information
about appropriate substitutions for patients with drug allergies and concomitant medications
that should be avoided. The pharmacist’s scope of practice has expanded to incorporate
identification of alternative therapies to reduce cost or increase safety, prescribing
privileges, vaccination services, and management for patients with complex drug
regimens.20–26 Therefore, monitoring PGx information to assure appropriate drug dosing is
a natural extension of the role of pharmacists.27–29 Indeed, schools of pharmacy30–32 and
continuing education programs33 have begun to recognize the importance of education on
PGx testing. A handful of studies have begun to explore the role of pharmacists and the use
of PGx testing.34,35
Despite the expanded scope of pharmacy practices, the structure of an appropriate
collaborative partnership between pharmacists and physicians is not yet well-defined36–39,
particularly with community pharmacists.40,41 Pharmacists’ limited access to a patient’s
medical history and other test results will hinder their ability to determine the need for PGx
testing and use of alternative medication. In addition, different business models of
prescription filling (e.g., mail order, wholesale, retail) may not be amenable to a
collaborative role between physicians and pharmacists with respect to PGx testing.
Like drug allergy information, PGx test results could be routinely stored in a patient’s
pharmacy record. The majority of respondents indicated they were willing to have their
results shared with a pharmacist, though significantly fewer than those willing to have their
results shared with other physicians, perhaps due to their limited relationship with
pharmacists.42 Although pharmacists, along with physicians, have been ranked as the two
most trusted sources of drug information by patients,43 the public’s understanding of the
services they may provide in addition to dispensing medication is limited,44,45 possibly
attributing to the lower level of comfort indicated in our survey. In addition, potential patient
concerns about privacy could further account for the lower level of comfort,46 particularly if
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patients’ recognize that their results may be placed in an electronic pharmacy dispensing
system. However, since we did not ask survey respondents about electronic data storage
such as EHRs, it is still speculative what factors account for the differing levels of comfort.
In the event that a drug is ordered for which a PGx test is required or strongly
recommended, a pharmacist may have an obligation to alert the prescribing physician about
testing and/or confirm that the test was ordered. The potential of increased medical liability
due to harms caused by failure to consider PGx testing has been considered in depth
elsewhere,47 for which the defendants may include the drug manufacturer, insurance
companies, physicians, and potentially pharmacists.
While patients and pharmacists do play an important role in the medication process, the
physician remains the central agent of most medication selection and prescribing. Thus,
directly influencing physician prescribing practices will be critical for ensuring the
appropriate consideration of PGx factors. In particular, EHRs and their component sub-
systems (e.g., e-Prescribing modules) provide ideal contexts for storing PGx data and using
them to influence physician prescribing behaviors. Critical to such EHR-supported, PGx-
enabled personalized prescribing will be the establishment of a national health information
technology infrastructure that includes the use of common data and terminology standards
and the establishment of up-to-date, clinically relevant knowledge resources for how PGx
results should be used to guide clinical care.48,49 While there are significant challenges to
establishing such an infrastructure, an EHR-based approach to storing and using PGx results
is highly promising. In particular, significant progress could be made if interoperability
supportive of personalized pharmacotherapy is appropriately included as a core requirement
in the federal government’s current efforts to finance the widespread adoption of EHRs in
the United States.50
Whether through personal health records, pharmacy information systems, or EHR systems,
the routine provision of PGx guidance will require the widespread availability of rigorously
curated knowledge on how patients’ PGx test results should influence medication selection
and dosing. Currently, commercial medication knowledge bases from companies such as
First DataBank, Multum, and Medi-Span are widely integrated with pharmacy information
systems and EHR systems to provide pharmacists and physicians with pharmacotherapy
guidance. Thus, if one or more of these commercial offerings were to begin to incorporate
PGx knowledge, and if PGx testing data were to be widely collected in a standardized
manner, PGx could be incorporated into routine clinical practice through the leveraging of
significant existing infrastructure and processes.
In moving forward, it will be important to keep in mind that the approaches we have
outlined here are complementary rather than competitive. Patients, pharmacists, and
physicians are all critical players in the pharmacotherapy process, and it will be important to
acknowledge that the most effective approaches will likely involve a combination of such
strategies as the use of personal health records, EHRs, and the pharmacy dispensing system
with a database to track PGx results. Critical will be the use of common standards to enable
interoperability across these various systems, as well as appropriate privacy and security
safeguards to ensure that the wishes of patients are properly honored as PGx information
becomes a more widely available and increasingly important consideration in the safe and
effective prescribing of pharmacotherapies.
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